Skip to main content

Pharmacokinetics of Melatonin: The Missing Link in Clinical Efficacy?

Abstract

Despite widespread clinical application of melatonin, several unanswered questions remain regarding the pharmacokinetics of this drug. This lack of knowledge may contribute to the inconsistency of results in previous clinical studies. Currently, a t max value of 30–45 min and a t ½elimination of 45 min are well established. Several questions relate to what constitutes a clinically effective plasma concentration, the choice of ideal administration route, and the optimal method of analysis. Furthermore, investigations of melatonin metabolites in humans are urgently needed in order to characterize their biological functions and the metabolic fates of these derivatives. Finally, pharmacokinetics in patients should be investigated further in order to reduce the risk of potential adverse effects, such as daytime sleepiness or unintended sedation.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Brzezinski A, Vangel MG, Wurtman RJ, Norrie G, Zhdanova I, Ben-Shushan A, et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev. 2005;9:41–50.

    Article  PubMed  Google Scholar 

  2. 2.

    Grossman E, Laudon M, Yalcin R, Zengil H, Peleg E, Sharabi Y, et al. Melatonin reduces night blood pressure in patients with nocturnal hypertension. Am J Med. 2006;119:898–902.

    CAS  Article  PubMed  Google Scholar 

  3. 3.

    Koziróg M, Poliwczak AR, Duchnowicz P, Koter-Michalak M, Sikora J, Broncel M. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. J Pineal Res. 2011;50:261–6.

    Article  PubMed  Google Scholar 

  4. 4.

    De Matos Cavalcante AG, de Bruin PF, de Bruin VM, Nunes DM, Pereira ED, Cavalcante MM, et al. Melatonin reduces lung oxidative stress in patients with chronic obstructive pulmonary disease: a randomized, double-blind, placebo-controlled study. J Pineal Res. 2012;53:238–44.

    Article  PubMed  Google Scholar 

  5. 5.

    Song GH, Leng PH, Gwee KA, Moochhala SM, Ho KY. Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study. Gut. 2005;54:1402–7.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  6. 6.

    Andersen LPH, Werner MU, Rosenberg J, Gögenur I. A systematic review of peri-operative melatonin. Anaesthesia. 2014;69:1163–71.

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Gögenur I, Kücükakin B, Panduro Jensen L, Reiter RJ, Rosenberg J. Melatonin reduces cardiac morbidity and markers of myocardial ischemia after elective abdominal aortic aneurism repair: a randomized, placebo-controlled, clinical trial. J Pineal Res. 2014;57:10–5.

    Article  PubMed  Google Scholar 

  8. 8.

    Gitto E, Romeo C, Reiter RJ, Impellizzeri P, Pesce S, Basile M, et al. Melatonin reduces oxidative stress in surgical neonates. J Pediatr Surg. 2004;39:184–9.

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Gitto E, Karbownik M, Reiter RJ, Tan DX, Cuzzocrea S, Chiurazzi P, et al. Effects of melatonin treatment in septic newborns. Pediatr Res. 2001;50:756–60.

    CAS  Article  PubMed  Google Scholar 

  10. 10.

    Bellapart J, Boots R. Potential use of melatonin in sleep and delirium in the critically ill. Br J Anaesth. 2012;108:572–80.

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    Srinivasan V, Pandi-Perumal SR, Trahkt I, Spence DW, Poeggeler B, Hardeland R, et al. Melatonin and melatonergic drugs on sleep: possible mechanisms of action. Int J Neurosci. 2009;119:821–46.

    CAS  Article  PubMed  Google Scholar 

  12. 12.

    Srinivasan V, Pandi-Perumal SR, Spence DW, Kato H, Cardinali DP. Melatonin in septic shock: some recent concepts. J Crit Care. 2010;25(656):e1–6.

    PubMed  Google Scholar 

  13. 13.

    Garaulet M, Gómez-Abellán P, Rubio-Sastre P, Madrid JA, Saxena R, Scheer FA. Common type 2 diabetes risk variant in MTNR1B worsens the deleterious effect of melatonin on glucose tolerance in humans. Metabolism. 2015;64:1650–7.

    CAS  Article  PubMed  Google Scholar 

  14. 14.

    Arendt J, Skene DJ. Melatonin as a chronobiotic. Sleep Med Rev. 2005;9:25–39.

    Article  PubMed  Google Scholar 

  15. 15.

    Andersen LPH, Rosenberg J, Gögenur I. Perioperative melatonin: not ready for prime time. Br J Anaesth. 2014;112:7–8.

    CAS  Article  PubMed  Google Scholar 

  16. 16.

    Harpsøe NG, Andersen LPH, Gögenur I, Rosenberg J. Clinical pharmacokinetics of melatonin: a systematic review. Eur J Clin Pharmacol. 2015;71:901–9.

    Article  PubMed  Google Scholar 

  17. 17.

    Cavallo A, Ritschel WA. Pharmacokinetics of melatonin in human sexual maturation. J Clin Endocrinol Metab. 1996;81:1882–6.

    CAS  PubMed  Google Scholar 

  18. 18.

    Bourne RS, Mills GH, Minelli C. Melatonin therapy to improve nocturnal sleep in critically ill patients: encouraging results from a small randomised controlled trial. Crit Care. 2008;12:R52.

    Article  PubMed  PubMed Central  Google Scholar 

  19. 19.

    Di WL, Kadva A, Johnston A, Silman R. Variable bioavailability of oral melatonin. N Engl J Med. 1997;336:1028–9.

    CAS  Article  PubMed  Google Scholar 

  20. 20.

    Andersen LP, Werner MU, Rosenkilde MM, Harpsøe NG, Fuglsang H, Rosenberg J, et al. Pharmacokinetics of oral and intravenous melatonin in healthy volunteers. BMC Pharmacol Toxicol. 2016;17:8.

    Article  PubMed  PubMed Central  Google Scholar 

  21. 21.

    Härtter S, Grözinger M, Weigmann H, Röschke J, Hiemke C. Increased bioavailability of oral melatonin after fluvoxamine coadministration. Clin Pharmacol Ther. 2000;67:1–6.

    Article  PubMed  Google Scholar 

  22. 22.

    Härtter S, Nordmark A, Rose DM, Bertilsson L, Tybring G, Laine K. Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity. Br J Clin Pharmacol. 2003;56:679–82.

    Article  PubMed  PubMed Central  Google Scholar 

  23. 23.

    Hilli J, Korhonen T, Turpeinen M, Hokkanen J, Mattila S, Laine K. The effect of oral contraceptives on the pharmacokinetics of melatonin in healthy subjects with CYP1A2 g.-163C > A polymorphism. J Clin Pharmacol. 2008;48:986–94.

    CAS  Article  PubMed  Google Scholar 

  24. 24.

    Lane EA, Moss HB. Pharmacokinetics of melatonin in man: first pass hepatic metabolism. J Clin Endocrinol Metab. 1985;61:1214–6.

    CAS  Article  PubMed  Google Scholar 

  25. 25.

    Stefani LC, Muller S, Torres IL, Razzolini B, Rozisky JR, Fregni F, et al. A phase II, randomized, double-blind, placebo controlled, dose-response trial of the melatonin effect on the pain threshold of healthy subjects. PLoS One. 2013;8:e74107.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  26. 26.

    Yaprak M, Altun A, Vardar A, Aktoz M, Ciftci S, Ozbay G. Decreased nocturnal synthesis of melatonin in patients with coronary artery disease. Int J Cardiol. 2003;89:103–7.

    Article  PubMed  Google Scholar 

  27. 27.

    Hikichi T, Tateda N, Miura T. Alteration of melatonin secretion in patients with type 2 diabetes and proliferative diabetic retinopathy. Clin Ophthalmol. 2011;5:655–60.

    Article  PubMed  PubMed Central  Google Scholar 

  28. 28.

    Schernhammer ES, Hankinsin SE. Urinary melatonin levels postmenopausal breast cancer risk in the nurses’ health study cohort. Cancer Epidemiol Biomark Prev. 2009;18:74–9.

    CAS  Article  Google Scholar 

  29. 29.

    Galano A, Tan DX, Reiter RJ. On the free radical scavenging activities of melatonin’s metabolites, AFMK and AMK. J Pineal Res. 2013;54:245–57.

    CAS  Article  PubMed  Google Scholar 

  30. 30.

    Mistraletti G, Sabbatini G, Taverna M, Figini MA, Umbrello M, Magni P, et al. Pharmacokinetics of orally administered melatonin in critically ill patients. J Pineal Res. 2010;48:142–7.

    CAS  Article  PubMed  Google Scholar 

  31. 31.

    Bellapart J, Roberts JA, Appadurai V, Wallis SC, Nuñez-Nuñez M, Boots RJ. Pharmacokinetics of a novel dosing regimen of oral melatonin in critically ill patients. Clin Chem Lab Med. 2016;54:467–72.

    CAS  Article  PubMed  Google Scholar 

  32. 32.

    Gooneratne NS, Edwards AYZ, Zhou C, Cuellar N, Grandner MA, Barrett JS. Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults. J Pineal Res. 2012;52:437–45.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  33. 33.

    Reiter R, Tan DX, Zhou Z, Cruz M, Fuentes-Broto L, Galano A. Phytomelatonin: assisting plants to survive and thrive. Molecules. 2015;20:7396–437.

    CAS  Article  PubMed  Google Scholar 

  34. 34.

    Tan DX, Zanghi BM, Manchester LC, Reiter RJ. Melatonin identified in meats and other food stuffs: potentially nutritional impact. J Pineal Res. 2014;57:213–8.

    CAS  Article  PubMed  Google Scholar 

  35. 35.

    Ursing C, von Bahr C, Brismar K, Röjdmark S. Influence of cigarette smoking on melatonin levels in man. Eur J Clin Pharmacol. 2005;61:197–201.

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Lars Peter Holst Andersen.

Ethics declarations

Funding

No external funding was used in the preparation of this manuscript.

Conflicts of interest

Lars P. H. Andersen, Ismail Gögenur, Jacob Rosenberg and Russel J. Reiter declare that they have no conflicts of interest that might be relevant to the contents of this article.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Andersen, L.P.H., Gögenur, I., Rosenberg, J. et al. Pharmacokinetics of Melatonin: The Missing Link in Clinical Efficacy?. Clin Pharmacokinet 55, 1027–1030 (2016). https://doi.org/10.1007/s40262-016-0386-3

Download citation

Keywords

  • Chronic Obstructive Pulmonary Disease
  • Melatonin
  • Fluvoxamine
  • Daytime Sleepiness
  • Liver Cirrhosis Patient